Extended O6-Methylguanine methyltransferase promoter hypermethylation following n-butylidenephthalide combined with 1, 3-Bis(2-chloroethyl)-1-nitrosourea (BCNU) on inhibition of human hepatocellular carcinoma cell growth

Journal of Agricultural and Food Chemistry

Volumn 58, Issue 3, 2010, Pages 1630-1638

  Yu, Yung Luen ^a,b,c   Yu, Sung Liang ^c,d   Su, Kuo Jung ^c,e   Wei, Chyou Wei ^f   Jian, Min Hui ^e   Lin, Po Cheng ^g   Tseng, I Hsuan ^e   Lin, Chai Ching ^e   Su, Chin Cheng ^h   Chan, De Chuan ⁱ   Lin, Shinn Zong ^j   Harn, Horng Jyh ^j   Chen, Yi Lin Sophia ^e  

^a Center for Molecular Medicine   (China)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c ASIA UNIVERSITY   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^e NATIONAL ILAN UNIVERSITY   (Taiwan)

^f HUNGKUANG UNIVERSITY   (Taiwan)

^g NATIONAL DONG HWA UNIVERSITY   (Taiwan)

^h BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

ⁱ TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^j CHINA MEDICAL UNIVERSITY   (Taiwan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANGELICA SINENSIS;

ANTINEOPLASTIC AGENT; BUTYLIDENEPHTHALIDE; CARMUSTINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PHTHALIC ANHYDRIDE; PLANT EXTRACT;

ANGELICA SINENSIS; ARTICLE; CELL PROLIFERATION; CHEMISTRY; DNA METHYLATION; DRUG EFFECT; ENZYMOLOGY; GENETICS; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; PATHOPHYSIOLOGY; TUMOR CELL LINE;

ANGELICA SINENSIS; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CARMUSTINE; CELL LINE, TUMOR; CELL PROLIFERATION; DNA METHYLATION; HUMANS; LIVER NEOPLASMS; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; PHTHALIC ANHYDRIDES; PLANT EXTRACTS;

EID: 76449101151     PISSN: 00218561     EISSN: 15205118     Source Type: Journal    
DOI: 10.1021/jf903043r     Document Type: Article

References (29)

1. Stuart, K. E.; Anand, A. J.; Jenkins, R. L. Hepatocellular carcinoma in the United States. Prognostic features, treatment outcome, and survival. Cancer 1996, 77 (11), 2217-2222
2. Wilson, J. F. Liver cancer on the rise. Ann. Intern. Med. 2005, 142 (12, Part 1), 1029-1032
3. (3) Ye, Y. N.; Liu, E. S.; Li, Y.; So, H. L.; Cho, C. C.; Sheng, H. P.; Lee, S. S.; Cho, C. H. Protective effect of polysaccharides-enriched fraction from Angelica sinensis on hepatic injury. Life Sci. 2001, 69 (6), 637-646 (Pubitemid 32673622)
4. Yim,T. K.; Wu, W. K.; Pak, W. F.; Mak, D. H.; Liang, S. M.; Ko, K. M. Myocardial protection against ischaemia-reperfusion injury by a Polygonum multiflorum extract supplemented 'Dang-Gui decoction for enriching blood', a compound formulation, ex vivo. Phytother. Res. 2000, 14 (3), 195-199
5. Tsai, N. M.; Lin, S. Z.; Lee, C. C.; Chen, S. P.; Su, H. C.; Chang, W. L.; Ham, H. J. The antitumor effects of Angelica sinensis on malignant brain tumors in vitro and in vivo. Clin. Cancer Res. 2005, 11 (9), 3475-3484
6. Tsai, N. M.; Chen, Y. L.; Lee, C. C.; Lin, P. C.; Cheng, Y. L.; Chang, W. L.; Lin, S. Z.; Harn, H. J. The natural compound n-butylidenephthalide derived from Angelica sinensis inhibits malignant brain tumor growth in vitro and in vivo. J. Neurochem. 2006, 99 (4), 1251-1262
7. Chen, Y. L.; Jian, M. H.; Lin, C. C.; Kang, J. C.; Chen, S. P.; Lin, P. C.; Hung, P. J.; Chen, J. R.; Chang, W. L.; Lin, S. Z.; Harn, H. J. The induction of orphan nuclear receptor Nur77 expression by n-butylenephthalide as pharmaceuticals on hepatocellular carcinoma cell therapy. Mol Pharmacol. 2008, 74 (4), 1046-1058
8. Lin, P. C.; Chen, Y. L.; Chiu, S. C.; Yu, Y. L.; Chen, S. P.; Chien, M. H.; Chen, K. Y.; Chang, W. L.; Lin, S. Z.; Chiou, T. W.; Harn, H.J. Orphan nuclear receptor, Nurr-77 was a possible target gene of butylidenephthalide chemotherapy on glioblastoma multiform brain tumor. J. Neurochem. 2008,106 (3), 1017-1026
9. Esteller, M.; Gaidano, G.; Goodman, S. N.; Zagonel, V.; Capello, D.; Botto, B.; Rossi, D.; Gloghini, A.; Vitolo, U.; Carbone, A.; Baylin, S. B.; Herman, J. G. Hypermethylation of the DNA repair gene O(6)-methylguanine DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma. J. Natl. Cancer Inst. 2002, 94 (1), 26-32.
10. Esteller, M.; Toyota, M.; Sanchez-Cespedes, M.; Capella, G.; Peinado, M. A.; Watkins, D. N.; Issa, J. P.; Sidransky, D.; Baylin, S. B.; Herman, J. G. Inactivation of the DNA repair gene O6methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis. Cancer Res. 2000, 60 (9), 2368-2371
11. Cai, S.; Xu, Y.; Cooper, R. J.; Ferkowicz, M. J.; Hartwell, J. R.; Pollok, K. E.; Kelley, M. R. Mitochondrial targeting of human O6methylguanine DNA methyltransferase protects against cell killing by chemotherapeutic alkylating agents. Cancer Res. 2005, 65 (8), 3319-3327
12. (12) Stupp, R.; van den Bent, M. J.; Hegi, M. E. Optimal role of temozolomide in the treatment of malignant gliomas. Curr. Neurol. Neurosci. Rep. 2005, 5 (3), 198-206. (Pubitemid 40873035)
13. (13) Hegi, M. E.; Diserens, A. C.; Gorlia, T.; Hamou, M. F.; de Tribolet, N.; Weller, M.; Kros, J. M.; Hainfellner, J. A.; Mason, W.; Mariani, L.; Bromberg, J. E.; Hau, P.; Mirimanoff, R. O.; Cairncross, J. G.; Janzer, R. C.; Stupp, R. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 2005, 352 (10), 997-1003. (Pubitemid 40349502)
14. Chou, T. C.; Talalay, P. Generalized equations for the analysis of inhibitions of Michaelis-Menten and higher-order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors. Eur. J. Biochem. 1981, 115 (1), 207-216
15. Chou, T. C.; Talalay, P. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 1984, 22, 27-55.
16. Chen, S. P.; Chiu, S. C.; Wu, C. C.; Lin, S. Z.; Kang, J. C.; Chen, Y. L.; Lin, P. C.; Pang, C. Y.; Harn, H. J. The Association of Methylation in the Promoter of APC and MGMT and the Prognosis of Taiwanese CRC Patients. Genet. Test. Mol. Biomarkers 2009, 13 (1), 67-71.
17. van Engeland, M.; Nieland, L. J.; Ramaekers, F. C.; Schutte, B.; Reutelingsperger, C. P. Annexin V-affinity assay: A review on an apoptosis detection system based on phosphatidylserine exposure. Cytometry 1998, 31 (1), 1-9.
18. Pieper, R. O.; Costello, J. F.; Kroes, R. A.; Futscher, B. W.; Marathi, U.; Erickson, L. C. Direct correlation between methylation status and expression of the human O-6-methylguanine DNA methyltransferase gene. Cancer Commun 1991, 3 (8), 241-253
19. Cairns-Smith, S.; Karran, P. Epigenetic silencing of the DNA repair enzyme O6-methylguanine-DNA methyltransferase in Mex- human cells. Cancer Res. 1992, 52 (19), 5257-5263
20. Wang, Y.; Kato, T.; Ayaki, H.; Ishizaki, K.; Tano, K.; Mitra, S.; Ikenaga, M. Correlation between DNA methylation and expression of O6-methylguanine-DNA methyltransferase gene in cultured human tumor cells. Mutat. Res. 1992, 273 (2), 221-230
21. Qian, X.; von Wronski, M. A.; Brent, T. P. Localization of methylation sites in the human O6-methylguanine-DNA methyltransferase promoter: correlation with gene suppression. Carcinogenesis 1995, 16 (6), 1385-1390
22. (22) Liu, L.; Allay, E.; Dumenco, L. L.; Gerson, S. L. Rapid repair of O6-methylguanine-DNA adducts protects transgenic mice from N-methylnitrosourea- induced thymic lymphomas. Cancer Res. 1994, 54 (17), 4648-4652 (Pubitemid 24276488)
23. Wu, M.; Kelley, M. R.; Hansen, W. K.; Martin, W. J. 2nd Reduction of BCNU toxicity to lung cells by high-level expression of O(6)-methylguanine-DNA methyltransferase. Am. J. Physiol. Lung Cell Mol. Physiol. 2001, 250 (4), L755-61.
24. Zielske, S. P.; Gerson, S. L. Lentiviral transduction of P140K MGMT into human CD34(+) hematopoietic progenitors at low multiplicity of infection confers significant resistance to BG/BCNU and allows selection in vitro. Mol. Ther. 2002, 5 (4), 381-387
25. Kaina, B.; Christmann, M.; Naumann, S.; Roos, W. P. MGMT: Key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents. DNA Repair 2007, 6 (8), 1079-1099
26. Williams, D. A.; Maze, R.; Kurpad, C.; Pegg, A.; Erickson, L. C. Protection of hematopoietic cells against combined O6-benzylguanine and chloroethylnitrosourea treatment by mutant forms of O6-methylguanine DNA methyltransferase. Bone Marrow Transplant. 2000, 25 (Suppl 2), S105-9.
27. Weingart, J.; Grossman, S. A.; Carson, K. A.; Fisher, J. D.; Delaney, S. M.; Rosenblum, M. L.; Olivi, A.; Judy, K.; Tatter, S. B.; Dolan, M. E. Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trial. J. Clin. Oncol. 2007, 25 (4), 399-404.
28. (28) Warren, K. E.; Aikin, A. A.; Libucha, M.; Widemann, B. C.; Fox, E.; Packer, R. J.; Balis, F. M. Phase I study of O6-benzylguanine and temozolomide administered daily for 5 days to pediatric patients with solid tumors. J. Clin. Oncol. 2005, 23 (30), 7646-7653 (Pubitemid 46291829)
29. Kuo, C. C.; Liu, J. F.; Chang, J. Y. DNA repair enzyme, O6-methylguanine DNA methyltransferase, modulates cytotoxicity of camptothecin-derived topoisomerase I inhibitors. J. Pharmacol. Exp. Ther. 2006, 316 (2), 946-954